Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
NEW YORK, July 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
Summary
GBI Research in its present report "Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth" describes generic market in antiviral therapeutics. This report covers antiviral therapeutics including HIV therapeutics, Hepatitis therapeutics, Herpes therapeutics, CMV therapeutics and Influenza therapeutics. Generics in antiviral market are forecast to grow at a CAGR of 10.5% during 2010-2018, largely due to series of patent expiries in the antiviral market. In 2010 generic HIV/AIDS therapeutic market sales contributes 46% market share in the total generic antiviral therapeutic market followed by generic herpes therapeutic market with 39.6% of market share. It is estimated that in 2010, generics accounted for 18.9% of market share in global antivirals market, and this market share is forecast to grow and reach 29.2% by 2018.
Generics in global antivirals market are estimated to be $4.2 billion in 2010 and are forecast to grow at a CAGR of 10.5% and reach $9.2 billion by 2018. From 2004, the market grew at a CAGR of 21.1% to reach $4.2 billion in 2010. Global generic antiviral market is comprised of revenues generated by various generic antiviral drugs. In 2010, it is estimated that generics in HIV market accounted for largest market share in total generic antivirals market. Generics in HIV market accounted for 46% of market share in total generic antivirals market in 2010, while generic herpes therapeutics accounted for 39.6% of market share. Generic influenza therapeutics accounted for 1% of total market share. Generic CMV market holds about 9.6% of share in total antiviral generic market, while generic hepatitis market accounted for only 3.9% of market share.
Series of patent expiries of key antiviral drugs will positively impact the market. Increase in patient population, reforms in government policies towards the use of generic drugs could be other major drivers of the market during the forecast period.
GBI Research projects that global generic HIV market will grow at a CAGR of 6.7% during 2010-2018. Growth in the market could be attributed to loss of patent exclusivity of key antiviral drugs. The market is currently dominated by products such as zidovudine, didanosine, stavudine and lamivudine. Launch of Combivir (lamivudine/Zidovudine) is expected soon, which can significantly influence the market.
GBI Research forecast's that global generic herpes market will grow at a CAGR of 9% during 2010-2018. Global generic herpes therapeutics market grew at a rapid rate of 32.4% from 2004 to 2010. The market revenue during this period was driven primarily by generic product such as acyclovir. In 2009, after patent expiry of Valtrex (valacyclovir), its generic equivalents were launched. In 2010, Famvir (famciclovir), potent antiviral from Novartis lost its patent exclusivity and its generic equivalents are currently available. In April, 2011, Mylan launched generic version of famciclovir.
Scope
- Data and analysis on the global generics in antivirals market
- Market forecasts for the global generics in antivirals market until 2018
- Market Data on geographical landscape including country wise coverage, cost of therapy, market size and market share.
- Key drivers and restraints that have created significant impact on the market.
- Competitive landscape of the global generics in antivirals market including top companies profiles. The key companies studied in this report are Teva Pharmaceuticals, Aurobindo Pharma, Mylan Inc and Watson Pharmaceuticals.
- Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the global generics in antivirals market.
Reasons to buy
The report will aid business development and marketing executives strategizing their product launches -
- Build effective strategies to launch their generics antiviral products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
3 Generics in Antivirals Market to 2018 - Market Overview 12
3.1 Introduction 12
3.2 Generic in Antivirals Market, Global Revenues 14
3.2.1 Revenue 14
3.2.2 Annual Cost of Treatment 18
3.2.3 Treatment Usage Pattern 19
3.2.4 Drivers and Restraints for Generic Antiviral Market 21
4 Generics in Antivirals Market to 2018 - Geographical Landscape 23
4.1 The US 23
4.1.1 Revenue 23
4.1.2 Treatment Usage Pattern 24
4.2 Top Five Countries of Europe 26
4.2.1 Revenue 26
4.2.2 Treatment Usage Pattern 29
4.3 Japan 31
4.3.1 Revenue 31
4.3.2 Treatment Usage Pattern 32
5 Generics in Antiviral Market to 2018 - Therapeutic Landscape 34
5.1 Global Generic HIV Therapeutics Market 34
5.1.1 Introduction 34
5.1.2 Revenue 35
5.1.3 Annual Cost of Treatment 40
5.1.4 Treatment Flow Algorithm 41
5.1.5 Treatment Usage Pattern 42
5.1.6 Drivers and Restraints for Generic HIV Market 44
5.2 Global Generic Hepatitis Therapeutics Market 45
5.2.1 Introduction 45
5.2.2 Revenue 47
5.2.3 Annual Cost of Treatment 51
5.2.4 Treatment Flow Algorithm 52
5.2.5 Treatment Usage Pattern 53
5.2.6 Drivers and Restraints for Generic Hepatitis Market 55
5.3 Global Generic Herpes Therapeutics Market 56
5.3.1 Introduction 56
5.3.2 Revenue 58
5.3.3 Annual Cost of Treatment 62
5.3.4 Treatment Flow Algorithm 63
5.3.5 Treatment Usage Pattern 64
5.3.6 Drivers and Restraints for Generics in Herpes Therapeutics Market 66
5.4 Global Generic Cytomegalovirus Therapeutics Market 67
5.4.1 Introduction 67
5.4.2 Revenue 68
5.4.3 Annual Cost of Treatment 72
5.4.4 Treatment Usage Pattern 73
5.4.5 Drivers and Restraints for Cytomegalovirus Therapeutics Market 75
5.5 Global Generic Influenza Market 76
5.5.1 Introduction 76
5.5.2 Revenue 77
5.5.3 Annual Cost of Treatment 81
5.5.4 Treatment Flow Algorithm 82
5.5.5 Treatment Usage Pattern 83
5.5.6 Drivers and Restraints for Influenza Therapeutics Market 85
6 Generics in Antivirals Market to 2018 - Major Marketed Drugs Analysis 86
6.1 Major Generic Drugs in Antivirals Market 86
6.1.1 Ribavirin 86
6.1.2 Acyclovir 86
6.1.3 Valacyclovir 87
6.1.4 Famciclovir 87
6.1.5 Penciclovir 87
6.1.6 Didanosine 88
6.1.7 Lamivudine 88
6.1.8 Stavudine 88
6.1.9 Zidovudine 89
6.1.10 Zalcitabine 89
6.1.11 Amantadine 89
6.1.12 Rimantadine 90
6.1.13 Ganciclovir 90
6.1.14 Foscarnet 90
6.2 Major Marketed Products Expecting Loss of Patent Exclusivity 91
6.2.1 Introduction 91
6.2.2 Baraclude 92
6.2.3 Viread 92
6.2.4 Combivir 93
6.2.5 Sustiva 93
6.2.6 Kaletra 93
6.2.7 Reyataz 94
6.2.8 Epzicom 94
6.2.9 Prezista 94
6.2.10 Valcyte 95
6.2.11 Tamiflu 95
6.2.12 Atripla 95
6.2.13 Truvada 96
7 Generics in Antivirals Market to 2018 - Competitive Landscape 97
7.1 Competitive Profiling 97
7.1.1 Teva Pharmaceuticals 97
7.1.2 Aurobindo Pharma Ltd 98
7.1.3 Watson Pharmaceuticals 99
7.1.4 Mylan Inc 100
8 Generics in Antivirals Market to 2018 - Strategic Consolidations 101
8.1 Generics in Antivirals Market: Major Deals 101
8.1.1 Gilead Sciences Extends Licensing Agreement with Matrix Laboratories for Tenofovir, Elvitegravir, Cobicistat and Quad 101
8.1.2 Bristol-Myers Squibb Enters Into Co-Marketing Agreement with Matrix Laboratories 101
8.1.3 Tibotec Pharmaceuticals Enters Into Licensing Agreement with Matrix Laboratories for TMC278 102
8.1.4 Watson Pharmaceuticals Acquires Specifar Pharmaceuticals 102
8.1.5 Watson Enters into Licensing Agreement with Natco 102
8.1.6 Apotex Acquires Lareq Pharma from Industria Quimica Y Farmaceutica 102
8.1.7 Apotex Acquires Topgen from Zambon 103
8.1.8 Teva Pharmaceutical Industries Acquires Taiyo Pharmaceutical Industry 103
8.1.9 Teva Pharmaceutical Industries Acquires Corporacion Infarmasa 103
8.1.10 Teva Pharmaceutical Industries Completes Acquisition of ratiopharm 103
8.1.11 Teva Pharmaceutical Acquires Barr Pharmaceuticals 103
8.1.12 Teva Pharmaceutical Industries Signs Joint Venture Agreement with Kowa Company 104
8.1.13 Teva Pharmaceutical Acquires Bentley Pharmaceuticals 104
9 Generics in Antivirals Market to 2018 - Appendix 105
9.1 Market Definitions 105
9.2 Abbreviations 105
9.3 Sources 106
9.4 Research Methodology 106
9.4.1 Coverage 107
9.4.2 Secondary Research 107
9.4.3 Primary Research 107
9.4.4 Forecast 108
9.4.5 Expert Panel Validation 110
9.5 Contact Us 110
9.6 Disclaimer 110
1.1 List of Tables
Table 1: Generics in Antivirals Market, Global, Revenue by Indication ($m), 2004-2010 12
Table 2: Generics in Antivirals Market, Global, Revenue Forecast by Indication ($m), 2010-2018 13
Table 3: Generics in Antivirals Market, Global, Revenue ($bn), 2004-2010 14
Table 4: Generics in Antivirals Market, Global, Revenue Forecast ($bn), 2010-2018 15
Table 5: Generics in Antivirals Market, Global, Revenue by Geography ($m), 2004–2010 16
Table 6: Generics in Antivirals Market, Global, Revenue Forecast by Geography ($m), 2010-2018 17
Table 7: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2004-2010 18
Table 8: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2010-2018 18
Table 9: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2004–2018 19
Table 10: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2010-2018 20
Table 11: Generics in Antivirals Market, The US, Revenue ($m), 2004-2010 23
Table 12: Generics in Antivirals Market, The US, Revenue Forecast ($m), 2010-2018 23
Table 13: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2004–2010 24
Table 14: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2010-2018 24
Table 15: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue ($m), 2004-2010 26
Table 16: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast ($m), 2010-2018 26
Table 17: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue by Geography ($m), 2004–2010 27
Table 18: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast by Geography ($m), 2010-2018 27
Table 19: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2004–2010 29
Table 20: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2010–2018 29
Table 21: Generics in Antivirals Market, Japan, Revenue ($m), 2004-2010 31
Table 22: Generics in Antivirals Market, Japan, Revenue Forecast ($m), 2010-2018 31
Table 23: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2004–2010 32
Table 24: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2010–2018 32
Table 25: Generics in HIV Market, Global, Revenue ($m), 2004-2010 35
Table 26: Generics in HIV Market, Global, Revenue Forecast ($m), 2010-2018 35
Table 27: Generics in HIV Market, Global, Patent Expiry of Major Products, 2010-2018 36
Table 28: Generics in HIV Market, Global, Revenue by Geography ($m), 2004–2010 38
Table 29: Generics in HIV Market, Global, Revenue Forecast by Geography ($m), 2010–2018 39
Table 30: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2004-2010 40
Table 31: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2010-2018 40
Table 32: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2004–2010 42
Table 33: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2010–2018 43
Table 34: Generics in Hepatitis Market, Global, Revenue ($m), 2004-2010 47
Table 35: Generics in Hepatitis Market, Global, Revenue Forecast ($m), 2010-2018 47
Table 36: Generics in Hepatitis Market, Global, Patent Expiry of Major Products, 2010-2018 48
Table 37: Generics in Hepatitis Market, Global, Revenue by Geography ($m), 2004–2010 49
Table 38: Generics in Hepatitis Market, Global, Revenue Forecast by Geography ($m), 2010–2018 50
Table 39: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2004-2010 51
Table 40: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2010-2018 51
Table 41: Generics in Hepatitis Market, Global, Treatment Usage Pattern ('000), 2004–2010 53
Table 42: Generics in Hepatitis Market, Global, Treatment Usage Pattern ('000), 2010–2018 54
Table 43: Generics in Herpes Therapeutics Market, Global, Revenue ($m), 2004-2010 58
Table 44: Generics in Herpes Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 58
Table 45: Generics in Herpes Therapeutics Market, Revenue by Geography ($m), 2004-2010 60
Table 46: Generics in Herpes Therapeutics Market, Revenue Forecast by Geography ($m), 2010-2018 61
Table 47: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 62
Table 48: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 62
Table 49: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004–2010 64
Table 50: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010–2018 64
Table 51: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue ($m), 2004-2010 68
Table 52: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 68
Table 53: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue by Geography ($m), 2004–2010 70
Table 54: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2010–2018 71
Table 55: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 72
Table 56: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 72
Table 57: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004–2010 73
Table 58: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2010–2018 73
Table 59: Generics in Influenza Therapeutics Market, Global, Revenue ($m), 2004-2010 77
Table 60: Generics in Influenza Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 77
Table 61: Generics in Influenza Therapeutics Market, Global, Revenue by Geography ($m), 2004–2010 79
Table 62: Generics in Influenza Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2010–2018 80
Table 63: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 81
Table 64: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 81
Table 65: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004–2010 83
Table 66: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010–2018 83
Table 67: Generics in Influenza Therapeutics Market, List of Marketed Products Expecting Loss of Patent Exclusivity 91
1.2 List of Figures
Figure 1: Generics in Antivirals Market, Global, Revenue Forecast by Indication ($m), 2004-2018 12
Figure 2: Generics in Antivirals Market, Global, Revenue Forecast ($bn), 2004-2018 14
Figure 3: Generics in Antivirals Market, Global, Revenue Forecast by Geography ($m), 2004–2018 16
Figure 4: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2004-2018 18
Figure 5: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2004–2018 19
Figure 6: Generics in Antivirals Market, Global, Drivers and Restraints 21
Figure 7: Generics in Antivirals Market, The US, Revenue Forecast ($m), 2004-2018 23
Figure 8: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2004–2018 24
Figure 9: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast ($m), 2004-2018 26
Figure 10: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast by Geography ($m), 2004–2018 27
Figure 11: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2004–2018 29
Figure 12: Generics in Antivirals Market, Japan, Revenue Forecast ($m), 2004-2018 31
Figure 13: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2004–2018 32
Figure 14: Generics in HIV Market, Global, Revenue Forecast ($m), 2004-2018 35
Figure 15: Generics in HIV Market, Global, Revenue Forecast by Geography ($m), 2004–2018 38
Figure 16: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2004-2018 40
Figure 17: Generics in HIV Market, HIV/AIDS Treatment Flow Algorithm, 2011 41
Figure 18: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2004–2018 42
Figure 19: Generics in HIV Market, Global, Drivers and Restraints 44
Figure 20: Generics in Hepatitis Market, Global, Revenue Forecast ($m), 2004-2018 47
Figure 21: Generics in Hepatitis Market, Global, Revenue Forecast by Geography ($m), 2004–2018 49
Figure 22: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2004-2018 51
Figure 23: Generics in Hepatitis Market, Hepatitis Treatment Flow Pathway, 2011 52
Figure 24: Generics in Hepatitis Market, Global, Treatment Usage Pattern (millions), 2004–2018 53
Figure 25: Generics in Hepatitis Market, Global, Drivers and Restraints 55
Figure 26: Generics in Herpes Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018 58
Figure 27: Generics in Herpes Therapeutics Market, Revenue Forecast by Geography ($m), 2004-2018 60
Figure 28: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 62
Figure 29: Generics in Herpes Therapeutics Market, Global, Treatment Algorithm,2011 63
Figure 30: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004–2018 64
Figure 31: Generics in Herpes Therapeutics, Global, Drivers and Restraints 66
Figure 32: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018 68
Figure 33: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2004–2018 70
Figure 34: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 72
Figure 35: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004–2018 73
Figure 36: Generics in Cytomegalovirus Therapeutics Market, Global, Drivers and Restraints 75
Figure 37: Generics in Influenza Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018 77
Figure 38: Generics in Influenza Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2004–2018 79
Figure 39: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 81
Figure 40: Generics in Influenza Therapeutics Market, Treatment Flow Algorithm for Influenza, 2011 82
Figure 41: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004–2018 83
Figure 42: Generics in Influenza Therapeutics Market, Global, Drivers and Restraints 85
Figure 43: Generics in Antiviral Market, Teva Pharmaceuticals SWOT Profile, 2011 97
Figure 44: Generics in Antiviral Market, Aurobindo Pharma SWOT Profile, 2011 98
Figure 45: Generics in Antiviral Market, Watson Pharmaceuticals SWOT Profile, 2011 99
Figure 46: Generics in Antiviral Market, Mylan Inc SWOT Profile, 2011 100
Figure 47: GBI Research Market Forecasting Model 109
Companies mentioned
Teva Pharmaceuticals
Aurobindo Pharma Ltd
Watson Pharmaceuticals
Mylan Inc
To order this report: Therapy Industry: Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article